简体中文(中国) 
English
Chinese (Simplified)
About Us
INmuneBio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Products
INKmune™
INKmune is a biologic delivery system that allows us to deliver the missing S1 (priming signal) to the patient’s resting NK cells. INKmune is delivered by a simple IV infusion.
Products
INB03
INB03 is a checkpoint inhibitor that targets myeloid-derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer.
Stay Tuned
Latest News
- Oct 17, 2018 INmune Bio Co-Founder and CSO Named Regional VP to the Board of International Society of Cell and Gene Therapy (ISCT)
- Sep 27, 2018 INmune Bio Named Finalist for Lifestars’ U.S. Private Company of the Year Award
- Sep 12, 2018 INmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., Chairing Sessions at International Society of Cell and Gene Therapy (ISCT) European Regional Meeting
| Have a Question? 858 964 3720 |
| Email Us dmoss@inmunebio.com |
| Opening Hours M - F 8am to 5pm PST |